The U.S. Sixth Circuit Court of Appeals confirmed a lower court’s decision on Wednesday to dismiss a challenge to the Medicare drug price negotiation program put forward by the U.S. Chamber of Commerce. The court reiterated that these officials had no standing to sue.
This ruling comes almost a year after a federal judge had previously dismissed a lawsuit from the Chamber, which contested the Medicare negotiation initiatives introduced by the Inflation Reduction Act.
The judge had reasoned that other plaintiffs in the case—the Dayton Regional Chamber of Commerce, the Ohio Chamber of Commerce, and the Michigan Chamber of Commerce—lacked the standing to represent their members. However, the U.S. Chamber of Commerce had filed a new lawsuit at a different venue, acting on its own.
The Court of Appeals largely supported the district court’s findings but emphasized a few key points.
It agreed that the Dayton Regional Chamber of Commerce had no relevance in this situation but made it clear that it wasn’t the only organization capable of challenging federal laws that may impact the community.
Last year, the district court determined that pharmaceutical firm Abbvie and its affiliated pharmacies did not have a direct connection to the business climate in Dayton, Ohio.
Still, the appeals court noted that companies often engage in markets far from their headquarters, suggesting that the absence of a geographical tie shouldn’t be seen as a decisive flaw in justifying their stance.
However, in this case, the court concluded that the absence of a headquarters and the “lack of a direct relationship with the purposes of the Dayton Chamber” was enough to invalidate the association of these entities.
The appeals court found that both the Dayton and Ohio Chambers of Commerce were not in a position to litigate the matter and agreed with the district court that it made no errors in its original ruling.
“Because the plaintiffs didn’t establish an appropriate venue elsewhere in Ohio, the district court correctly dismissed the case, as they could have relocated it if the Dayton and Ohio Chambers were not eligible,” the appeals court stated.
Following the loss at the appellate level, the U.S. Chamber of Commerce may still opt to take the case to the Supreme Court. Comments were sought from the U.S. Chamber regarding this development.
Advocacy groups supporting affordable drugs welcomed the ruling.
“This decision marks the tenth ruling from the court against a misguided legal challenge to the widely favored Medicare negotiation program in the pharmaceutical sector, which aims to provide lower prices to over 9 million patients across the country starting in January,” they stated.
“While the pharmaceutical industry spends millions to maintain its monopolistic pricing, the courts continue to reject attempts to challenge this,” an advocate remarked. “By upholding the lower court’s ruling, the U.S. Court of Appeals stands with American patients who deserve better deals amid an industry that seeks to hold them hostage.”
